High risks adverse events associated with usage of aspirin in chronic obstructive pulmonary disease

References

• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China pulmonary health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi: 10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a lancet commission. Lancet. 2022;400(10356):921–972. doi: 10.1016/S0140-6736(22)01273-9
   PubMed Web of Science ®Google Scholar
• MacDonald MI, Shafuddin E, King PT, et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):138–148. doi: 10.1016/S2213-2600(15)00509-3
   PubMed Web of Science ®Google Scholar
• Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi: 10.1016/S2213-2600(15)00241-6
   PubMed Web of Science ®Google Scholar
• Westerik JAM, Metting EI, Van Boven JFM, et al. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017;18(1):31. doi: 10.1186/s12931-017-0512-2
   PubMed Web of Science ®Google Scholar
• Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente medical care program. Chest. 2005;128(4):2068–2075. doi: 10.1378/chest.128.4.2068
   PubMed Web of Science ®Google Scholar
• Yang M, Li Y, Jiang Y, et al. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. Eur Respir J. 2023;61(2):2200302. doi: 10.1183/13993003.00302-2022
   PubMed Web of Science ®Google Scholar
• Bakshi A, Suissa S. Effectiveness of aspirin in COPD: biases in the observational studies. COPD: J Chronic Obstructive Pulmonary Dis. 2021;18(4):449–455. doi: 10.1080/15412555.2021.1963696
   PubMed Web of Science ®Google Scholar
• Chan SMH, Brassington K, Almerdasi SA, et al. Inhibition of oxidative stress by apocynin attenuated chronic obstructive pulmonary disease progression and vascular injury by cigarette smoke exposure. Br J Pharmacol. 2023;180(15):2018–2034. doi: 10.1111/bph.16068
   PubMed Web of Science ®Google Scholar
• Gawaz M. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378–3384. doi: 10.1172/JCI27196
   PubMed Web of Science ®Google Scholar
• Davì G, Basili S, Vieri M, et al. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care. 1997;156(6):1794–1799. doi: 10.1164/ajrccm.156.6.9706026
   PubMed Web of Science ®Google Scholar
• Harrison MT, Short P, Williamson PA, et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014;69(7):609–615. doi: 10.1136/thoraxjnl-2013-203996
   PubMed Web of Science ®Google Scholar
• Aaron CP, Schwartz JE, Hoffman EA, et al. A longitudinal cohort study of aspirin use and progression of Emphysema-like lung characteristics on CT imaging. Chest. 2018;154(1):41–50. doi: 10.1016/j.chest.2017.11.031
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Kirkby NS, Ahmetaj-Shala B, et al. Cyclooxygenases and the cardiovascular system. Pharmacol Ther. 2021;217:107624. doi: 10.1016/j.pharmthera.2020.107624
   PubMed Web of Science ®Google Scholar
• Fawzy A, Putcha N, Raju S, et al. Urine and plasma markers of platelet activation and Respiratory symptoms in COPD. J COPD F. 2023;10(1):22–32. doi: 10.15326/jcopdf.2022.0326
   PubMedGoogle Scholar
• Fawzy A, Putcha N, Aaron CP, et al. Aspirin use and Respiratory morbidity in COPD. Chest. 2019;155(3):519–527. doi: 10.1016/j.chest.2018.11.028
   PubMed Web of Science ®Google Scholar
• Pavasini R, Biscaglia S, d’Ascenzo F, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD: J Chronic Obstructive Pulmonary Dis. 2016;13(4):509–514. doi: 10.3109/15412555.2015.1099620
   PubMed Web of Science ®Google Scholar
• Short PM, Lipworth SIW, Elder DHJ, et al. Effect of blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342(may10 2):d2549–d2549. doi: 10.1136/bmj.d2549
   PubMedGoogle Scholar
• Campo G, Pavasini R, Malagù M, et al. Relationship between troponin elevation, cardiovascular history and adverse events in patients with acute exacerbation of COPD. COPD: J Chronic Obstructive Pulmonary Dis. 2015;12(5):560–567. doi: 10.3109/15412555.2014.995293
   PubMed Web of Science ®Google Scholar
• Hamid U, Krasnodembskaya A, Fitzgerald M, et al. Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS. Thorax. 2017;72(11):971–980. doi: 10.1136/thoraxjnl-2016-208571
   PubMed Web of Science ®Google Scholar
• Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66(9):769–774. doi: 10.1136/thx.2010.157529
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax. 1991;46(7):504–507. doi: 10.1136/thx.46.7.504
   PubMed Web of Science ®Google Scholar
• Mallah H, Ball S, Sekhon J, et al. Platelets in chronic obstructive pulmonary disease: an update on pathophysiology and implications for antiplatelet therapy. Respir med. 2020;171:106098. doi: 10.1016/j.rmed.2020.106098
   PubMed Web of Science ®Google Scholar
• Hodgson E. The effects of corticosteroids and nonsteroidal anti-inflammatory drugs, including aspirin, on coagulation. South Afr Family Pract. 2015;57(5):3. doi: 10.4102/safp.v57i5.4354
   Google Scholar
• Koomanan N, Ko Y, Yong W-P, et al. Clinical impact of drug–drug interaction between aspirin and prednisolone at a cancer center. Clin Ther. 2012;34(12):2259–2267. doi: 10.1016/j.clinthera.2012.11.002
   PubMed Web of Science ®Google Scholar
• Yang H, Liu Z, Li R, et al. The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database. Front Pharmacol. 2023;14:1259628. doi: 10.3389/fphar.2023.1259628
   PubMed Web of Science ®Google Scholar
• Zhang Y, Neogi T, Chen C, et al. Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis. 2014;73(2):385–390. doi: 10.1136/annrheumdis-2012-202589
   PubMed Web of Science ®Google Scholar
• Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. de Torres JP. ed. PLoS One. 2012;7(5):e37483. doi: 10.1371/journal.pone.0037483
   PubMed Web of Science ®Google Scholar
• Björklund L, Wallander M-A, Johansson S, et al. Aspirin in cardiology - benefits and risks. Int J Clin Pract. 2009;63(3):468–477. doi: 10.1111/j.1742-1241.2008.01908.x
   PubMed Web of Science ®Google Scholar
• Perlmutter JS. Moving the U.S. Food and drug administration Forward. Ann Intern Med. 2021;174(11):1626–1627. doi: 10.7326/M21-3393
   PubMed Web of Science ®Google Scholar
• Raisch DW, Garg V, Arabyat R, et al. Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and drug administration’s adverse event reporting system and review of case reports in the literature. Expert Opin Drug Saf. 2014;13(1):15–23. doi: 10.1517/14740338.2013.832752
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi: 10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Banda JM, Evans L, Vanguri RS, et al. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3(1):160026. doi: 10.1038/sdata.2016.26
   PubMedGoogle Scholar
• Poluzzi E, Raschi E, Piccinni C Data mining techniques in Pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting System (AERS). In: Karahoca A. editors, et al. Data mining applications in engineering and medicine. InTech; 2012. doi: 10.5772/50095
   Google Scholar
• Khaleel MA, Khan AH, Ghadzi SMS, et al. A standardized dataset of a spontaneous adverse event reporting System. Healthcare-Basel. 2022;10(3):420. doi: 10.3390/healthcare10030420
   PubMedGoogle Scholar
• Lin X, Yang J, Weng L, et al. Differences in hypersensitivity reactions to iodinated contrast media: analysis of the US Food and drug administration adverse event reporting System database. The Journal Of Allergy And Clinical Immunology In Practice. 2023;11(5):1494–1502.e6. doi: 10.1016/j.jaip.2023.01.027
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Naidoo V, Corzo L, et al. Genophenotypic factors and pharmacogenomics in adverse drug reactions. IJMS. 2021;22(24):13302. doi: 10.3390/ijms222413302
   Google Scholar
• Moyer AM, Matey ET, Miller VM. Individualized medicine: sex, hormones, genetics, and adverse drug reactions. Pharmacol Res Perspec. 2019;7(6):e00541. doi: 10.1002/prp2.541
   PubMed Web of Science ®Google Scholar
• Alharbi FF, Kholod AAV, Souverein PC, et al. The impact of age and sex on the reporting of cough and angioedema with renin–angiotensin system inhibitors: a case/noncase study in VigiBase. Fundamental Clinical Pharma. 2017;31(6):676–684. doi: 10.1111/fcp.12313
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–894. doi: 10.1158/1078-0432.CCR-15-1136
   PubMed Web of Science ®Google Scholar
• Hirata A, Saraya T, Kobayashi F, et al. Immune-related adverse events with immune checkpoint inhibitors: special reference to the effects on the lungs. Medicine. 2021;100(14):e25275. doi: 10.1097/MD.0000000000025275
   PubMed Web of Science ®Google Scholar
• Ren W, Wang W, Guo Y. Analysis of adverse reactions of aspirin in prophylaxis medication based on FAERS database. Ye X. ed. Comput Math Method M. 2022;2022:1–8. doi: 10.1155/2022/7882277
   Web of Science ®Google Scholar
• Huang Y, Li M, Li J-Y, et al. The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. Arumugam TV. ed. PLoS One. 2013;8(6):e65754. doi: 10.1371/journal.pone.0065754
   PubMed Web of Science ®Google Scholar
• Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163–173. doi: 10.1185/030079907X162656
   PubMed Web of Science ®Google Scholar
• Valkhoff VE, Sturkenboom MC, Hill C, et al. Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: a meta-analysis of randomized clinical trials and observational studies. Can J Gastroenterol. 2013;27(3):159–167. doi: 10.1155/2013/596015
   PubMed Web of Science ®Google Scholar
• Rybár I, Masaryk P, Mateicka F, et al. Nonsteroidal antiinflammatory drug-induced mucosal lesions of the upper gastrointestinal tract and their relationship to Helicobacter pylori. Int J Clin Pharmacol Res. 2001;21(3–4):119–125.
   PubMedGoogle Scholar
• Dahlén S-E, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by Montelukast, a Leukotriene Antagonist: a randomized, Double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9–14. doi: 10.1164/ajrccm.165.1.2010080
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312(23):2510. doi: 10.1001/jama.2014.15690
   PubMed Web of Science ®Google Scholar
• Weiss-Smith S. The FDA drug safety surveillance program: adverse event reporting trends. Arch Intern Med. 2011;171(6):591. doi: 10.1001/archinternmed.2011.89
   PubMedGoogle Scholar